Page 43 - Layout 1
P. 43
UTHSCSA
DEAN’S MESSAGE
formation or to refer a patient please call the CTRC clinical study
line at 210-450-5798.
explaining. It also includes “Panorama”, a restaurant with great views pediatric tumors and Lymphoma
of the city and northern hills, to serve faculty, staff and students of The new clinical trial with the drug atezolizumab will be offered
the Health Science Center and their guests.
to children ages 2 to 17 and young adults up to age 30 who have
We were honored to welcome San Antonio Mayor Ivy Taylor, and pediatric cancers. The focus will be on solid tumors and two types
Bexar County Judge Nelson Wolff at the dedication. Sara Martinez of lymphomas (Hodgkin lymphoma and Non-Hodgkin lym-
Tucker, a member of The University of Texas System Board of Re- phoma).
gents, accepted the building on behalf of the Regents and ceremo-
nially turned it over to UT Health Science Center President William Based on results from several clinical trials in adults, the U.S. Food
Henrich, MD. and Drug Administration in February granted Breakthrough Ther-
apy Designation for atezolizumab for treating non-small cell lung
First in U.S. Cancer trials cancer in adults. Atezolizumab also has shown good results against
We currently have two very significant cancer trials for which we a type of bladder cancer called metastatic urothelial carcinoma. The
drug is also being tested with numerous other types of cancer in
are the first-in-human study site in the United States. One is for adults. This trial is “A Single-Arm Study to Evaluate the Safety, Tol-
adult brain tumors and the other for pediatric solid tumors and lym- erability, Pharmacokinetics, Immunogenicity, and Preliminary Ef-
phoma. These trials are very recent innovations and actively seeking ficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and
new patients. A brief description of each is below. Please contact the Young Adult Participants With Solid Tumors.” For more informa-
research team if you would like to learn more or refer a patient. tion on eligibility and how to participate, contact Virginia Diaz
at diazvr@uthscsa.edu or 210-562-9149.
Adult Glioblastoma
The technology, developed at the Cancer Therapy & Research rare & historical Anatomy Book display –
April 12, 3-6pm
Center (CTRC), uses tiny radioactive liposomes (fat particles 100
nanometers in diameter), inserted by catheter directly into a tumor, Our P.I. Nixon Medical Historical Library will be holding an ex-
confining their radiation to the tumor tissue only. hibit of rare and historical anatomy texts. View a first edition of De
Humani Corporis Fabrica Libri Septem, by Andreas Vesalius, pub-
The trial is protocol number HSC20140450X; Title: “A Dual lished in 1543, and a 1481 edition of De Medicina by Aulus Cor-
Phase 1/2, Investigator Initiated Study to Determine the Maximum nelius Celsus, the Nixon Library’s oldest book. The display is open
Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes to the public.
(RNL) in Recurrent Glioblastoma (CTRC# 12-02).” For more in-
Featured Speaker
New York Times best-selling author, Damon Tweedy, M.D., will
talk about his book “Black Man in a White Coat: A Doctor’s Re-
flections on Race and Medicine”, Tuesday, April 19, 2016 in the
Holly Auditorium. Dr. Tweedy is a graduate of the Duke University
Medical School as well as Yale Law School. He is an assistant pro-
fessor of psychiatry at Duke University Medical Center and a staff
physician at the Durham VA Medical Center. His book was selected
as one of TIME Magazine’s top 10 non-fiction books of 2015. Pres-
entation begins at 12 noon followed by a 1 p.m. reception and book-
signing. Presented as part of the Frank Bryant Jr., M.D., Memorial
Lectures in Medical Ethics.
continued on page 44
visit us at www.bcms.org 43
